产品性状

BIIB021(CNF2024)是口服活性的HSP90抑制剂，Ki和EC50分别为1.7 nM和38 nM。溶解性：DMSO ≥60mg/mL Water <1.2mg/mL Ethanol ≥1.8mg/mL

质量标准

Oral administration of BIIB021 leads to tumor growth inhibition in many tumor xenograft models including N87, BT474, CWR22, U87, SKOV3 and Panc-1. BIIB021 effectively inhibits growth of L540cy tumor at a dose of 120 mg/kg. BIIB021 significantly enhances antitumor growth effect of radiation in JHU12 xenograft.